https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-23 / J. Virol. 2013 Apr;87(7):3792-800
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-23 / J. Virol. 2013 Apr;87(7):3792-8002013-01-23 00:00:002013-01-23 00:00:00Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-10 / Biofactors 2013 Jan-Feb;39(1):27-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-10 / Biofactors 2013 Jan-Feb;39(1):27-362013-01-10 00:00:002013-01-10 00:00:00Molecular mechanisms of curcumin action: signal transduction
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-10 / Biofactors 2013 Jan-Feb;39(1):56-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-10 / Biofactors 2013 Jan-Feb;39(1):56-682013-01-10 00:00:002013-01-10 00:00:00Curcumin in various cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-10 / Transl Res 2013 Apr;161(4):355-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-10 / Transl Res 2013 Apr;161(4):355-642013-01-10 00:00:002019-02-15 09:22:40Oncolytic virus therapy for cancer: the first wave of translational clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-01 / Acupunct Electrother Res 2013;38(3-4):161-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-01 / Acupunct Electrother Res 2013;38(3-4):161-972013-01-01 00:00:002013-01-01 00:00:00Oncothermia: a new paradigm and promising method in cancer therapies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-01 / Oncoimmunology 2013 Jan;2(1):e22664
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-01 / Oncoimmunology 2013 Jan;2(1):e226642013-01-01 00:00:002020-02-05 10:32:57Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
